Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A5381 TLD implementation outcomes study in PEPFAR-supported HIV care
PACTR202006835180506Not yet recruiting
- Sponsor
- AIDS Clinical Trials Group
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of dolutegravir, lamivudine, tenofovir and rifampicin in human immunodeficiency virus infection (HIV) and Tuberculosis (TB) (4 arms), sponsored by AIDS Clinical Trials Group. Primary endpoints: Virologic success at 6 months for Groups 1, 2, and 4, New dolutegravir resistance mutations at virologic failure for Groups 1, 2, and 4 and 2 more. Planned start Jul 2020; status: not yet recruiting.
02
Drugs
dolutegravirlamivudinetenofovirrifampicin
03
Conditions
human immunodeficiency virus infection (HIV)Tuberculosis (TB)
Beyond the preview
Go deeper on PACTR202006835180506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202006835180506.